- Home
- TEAF vs CGEN Comparison
TEAF vs CGEN Comparison
Compare TEAF & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEAF
- CGEN
- Stock Information
- Founded
- TEAF 2017
- CGEN 1993
- Country
- TEAF United States
- CGEN Israel
- Employees
- TEAF N/A
- CGEN N/A
- Industry
- TEAF Trusts Except Educational Religious and Charitable
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TEAF Finance
- CGEN Health Care
- Exchange
- TEAF Nasdaq
- CGEN Nasdaq
- Market Cap
- TEAF 174.8M
- CGEN 149.6M
- IPO Year
- TEAF N/A
- CGEN 2000
- Fundamental
- Price
- TEAF $11.36
- CGEN $1.46
- Analyst Decision
- TEAF
- CGEN Strong Buy
- Analyst Count
- TEAF 0
- CGEN 1
- Target Price
- TEAF N/A
- CGEN $4.00
- AVG Volume (30 Days)
- TEAF 56.1K
- CGEN 286.0K
- Earning Date
- TEAF 01-01-0001
- CGEN 03-04-2025
- Dividend Yield
- TEAF 9.20%
- CGEN N/A
- EPS Growth
- TEAF N/A
- CGEN N/A
- EPS
- TEAF N/A
- CGEN N/A
- Revenue
- TEAF N/A
- CGEN $27,864,000.00
- Revenue This Year
- TEAF N/A
- CGEN $22.94
- Revenue Next Year
- TEAF N/A
- CGEN $15.88
- P/E Ratio
- TEAF N/A
- CGEN N/A
- Revenue Growth
- TEAF N/A
- CGEN N/A
- 52 Week Low
- TEAF $11.11
- CGEN $1.35
- 52 Week High
- TEAF $13.30
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- TEAF 30.00
- CGEN 32.02
- Support Level
- TEAF $11.17
- CGEN $1.50
- Resistance Level
- TEAF $11.77
- CGEN $1.65
- Average True Range (ATR)
- TEAF 0.13
- CGEN 0.07
- MACD
- TEAF -0.03
- CGEN 0.00
- Stochastic Oscillator
- TEAF 31.91
- CGEN 12.50
About TEAF Ecofin Sustainable and Social Impact Term Fund
Tortoise Essential Assets Income Term is a US-based non-diversified, closed-end management investment company. Its investment objective is to provide common shareholders with a high level of total return with an emphasis on current distributions.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.